ArticleBlood advances2024

Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score-matched analysis.

Julia Driessen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.